Why the IDT Australia (ASX:IDT) share price is crashing 37% lower today

IDT shares are being hammered today…

| More on:

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

The IDT Australia Limited (ASX: IDT) share price is crashing down to Earth on Thursday morning.

At the time of writing, the pharmaceutical manufacturing company's shares are down 37% to 30 cents.

A woman screams and holds her hands up in frustration.

Image source: Getty Images

Why is the IDT Australia share price crashing today?

Investors have been selling down the IDT Australia share price today after it was dealt a bitter blow.

Earlier this year, the company announced that it successfully manufactured an mRNA drug product. This made IDT the first in Australia to manufacture a cGMP mRNA drug product.

In light of this, there were hopes that this would support its Australian Government Approach To Market submission to establish an onshore mRNA manufacturing capability (ATM).

However, this morning the Australian Government has confirmed that IDT's ATM submission has not been selected to progress to the next stage of the process.

IDT's CEO, Dr David Sparling, commented: "Whilst we are disappointed in the outcome of the ATM process, IDT has developed and progressed several alternative strategic options. The Company has successfully delivered on the Monash Institute of Pharmaceutical Sciences (MIPS) COVID-19 mRNA receptor binding domain vaccine candidate project, being Australia's first locally manufactured cGMP mRNA finished product and clearly showcases IDT's manufacturing capabilities in this regard."

What's next?

Dr Sparling notes that the company remains in the running for the Manufacturing Collaboration Stream Grant Opportunity.

"IDT is now sterile licenced and is maintaining its sterile facilities in a state of readiness to accept COVID-19 vaccine content at the Government's discretion. The Company is also waiting to receive feedback on its submission to the Australian Government's $800m Modern Manufacturing Initiative (MMI) Manufacturing Collaboration Stream Grant Opportunity," Dr Sparling added.

Positively, the company also stressed that the proposal is unaffected by the outcome of the ATM process. It will provide a market update if and when additional information comes to hand.

Motley Fool contributor James Mickleboro has no position in any of the stocks mentioned. The Motley Fool Australia's parent company Motley Fool Holdings Inc. has no position in any of the stocks mentioned. The Motley Fool Australia has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Bruce Jackson.

More on Healthcare Shares

Doctor sees virtual images of the patient's x-rays on a blue background.
Healthcare Shares

Why are Pro Medicus shares surging more than 10%?

The shares are still short of one broker's price target.

Read more »

Health professional looking at a laptop.
Earnings Results

Cogstate posts record FY26 earnings, boosts dividend

Cogstate delivers record FY26 earnings growth and increases its dividend as it invests in AI-driven expansion.

Read more »

Happy, tablet or doctor in a laboratory with research results or positive feedback after medical data analysis. Smile, vaccine or healthcare worker reading or working on futuristic science innovation.
Earnings Results

CSL earnings: FY26 sees reset and path to future growth

The biotech giant has released its eagerly anticipated results this morning.

Read more »

A man looking at his laptop and thinking.
Earnings Results

Cochlear posts FY26 profit at top end of guidance with new product momentum

Management is guiding to a profit rebound in FY 2027.

Read more »

Group of scientists cheering in the lab after the company received good news.
Healthcare Shares

Mesoblast shares are up sharply. Is this biotech still undervalued?

Mesoblast faces big risks, but brokers see substantial upside if successful.

Read more »

A scientist in a white coat and glasses puts her arms in the air in a sign of strength and success.
Healthcare Shares

Why is this ASX 300 healthcare stock up more than 17%?

Strong earnings have this company riding high.

Read more »

Two people comparing and analysing material.
Healthcare Shares

Could the CSL share price reach $200 in 2027?

It might sound ambitious after recent struggles, but the valuation required to get there is less demanding than you might…

Read more »

Two lab workers fist pump each other.
Healthcare Shares

Mesoblast share price jumps on blockbuster news

It has been a good start to the week for this biotech company.

Read more »